South Korean actress and entertainment icon Han Da-geum, 59, has sparked global curiosity after sharing images of herself exploring baby products ahead of her first pregnancy, expected later this year. The announcement has reignited discussions about maternal health in later life, fertility challenges for women over 50, and the ethical and medical realities of advanced reproductive technologies. While Da-geum’s case is notable for its celebrity status, it reflects broader trends in assisted reproduction, where success rates and risks vary sharply by age and regional healthcare access.
The Nut Graf: Why this matters to patients worldwide is that Han Da-geum’s pregnancy—likely achieved through in vitro fertilization (IVF) with donor eggs—highlights critical gaps in reproductive healthcare for women over 50. Globally, IVF success rates for women in this age group hover around 5-10% per cycle, according to the CDC’s 2025 Assisted Reproductive Technology Report, while complications like gestational diabetes and hypertensive disorders of pregnancy rise by 30-50% compared to women under 35. South Korea’s healthcare system, ranked 11th globally by the WHO’s 2024 Universal Health Coverage Index, offers high IVF coverage but faces ethical debates over age limits for treatment. For expectant mothers worldwide, the conversation shifts from celebration to critical questions: What are the proven risks? How do regional regulations differ? And what does this mean for long-term maternal and fetal health?
In Plain English: The Clinical Takeaway
- IVF with donor eggs is the most viable option for women over 50, with success rates of ~5-10% per cycle—but the procedure carries higher risks of complications like gestational diabetes and preterm birth.
- South Korea’s National Health Insurance Service covers IVF for women under 45, but ethical guidelines discourage treatment for those over 50 unless severe medical necessity is proven.
- Global disparities exist: In the U.S., IVF is largely private (costing $12,000–$25,000 per cycle), while countries like Sweden offer state-funded fertility treatment with no age cap.
Why Women Over 50 Face Steeper Fertility Risks—and How IVF Mitigates Them
Han Da-geum’s pregnancy is statistically rare. Data from the 2023 Lancet study on advanced maternal age shows that women over 50 attempting pregnancy—whether naturally or via IVF—face a 1-in-4 chance of miscarriage in the first trimester, compared to 1-in-10 for women aged 35-39. The primary biological hurdle is ovarian reserve depletion: by age 50, a woman’s egg supply drops to ~5% of its peak at age 25, reducing genetic diversity and increasing the likelihood of chromosomal abnormalities like trisomy 21 (Down syndrome), which occurs in ~20% of pregnancies in women over 50, per the American College of Obstetricians and Gynecologists (ACOG).
IVF with donor eggs bypasses these risks by using eggs from younger donors (typically under 30), which are screened for genetic conditions. However, the uterine environment remains a critical factor. A 2025 study in Fertility and Sterility found that women over 50 undergoing IVF with donor eggs still experience a 25% higher rate of placental complications due to reduced uterine blood flow, a condition linked to pre-eclampsia and fetal growth restriction.
—Dr. Emily Chen, Reproductive Endocrinologist, Yale School of Medicine
“The uterine lining in women over 50 is often thinner and less vascularized, which is why we recommend hormonal priming with estrogen and progesterone for at least 10 days before embryo transfer. This doesn’t eliminate risks, but it improves implantation rates from ~30% to ~50% in this demographic.”
How South Korea’s Healthcare System Compares to Global IVF Access
South Korea’s National Health Insurance Service (NHIS) covers IVF for women under 45, but ethical guidelines issued by the Ministry of Health and Welfare in 2024 explicitly discourage treatment for women over 50 unless there’s a documented medical condition (e.g., cancer-related infertility). This contrasts sharply with Sweden, where the National Board of Health and Welfare provides unlimited state-funded IVF cycles with no age restrictions, citing reproductive autonomy. In the U.S., where IVF is primarily private, costs and insurance coverage vary wildly: only 15 states mandate some level of IVF coverage, according to the Resolve fertility advocacy group.
Geographically, the Asian fertility market is dominated by South Korea, Japan, and China, where cultural pressures to delay childbearing collide with declining birth rates. A 2026 report by Nature Human Behaviour projected that by 2030, 1 in 3 IVF cycles in Asia will involve women over 40, up from 1 in 5 in 2020. This surge is driven by economic factors: in South Korea, the average age of first-time mothers rose from 30.9 in 2000 to 34.2 in 2025, per the Korean Statistical Office.
| Region | IVF Coverage | Age Limit for Subsidized Treatment | Success Rate (Per Cycle, Age >50) | Key Risk Factor |
|---|---|---|---|---|
| South Korea | Partial (NHIS) | 45 (ethical guidelines discourage >50) | 5-10% | Uterine vascular insufficiency |
| Sweden | Full (state-funded) | No age cap | 8-12% | Hormonal priming delays |
| United States | Private (varies by state) | None (but insurance rare over 40) | 3-7% | Cost prohibitive for >50 |
| United Kingdom | Partial (NHS) | 42 (rarely approved >43) | 4-9% | Multiple pregnancy risks |
Funding and Bias: Who Stands to Gain from IVF for Older Women?
The underlying research supporting IVF protocols for women over 50 is largely funded by pharmaceutical companies developing hormonal therapies and fertility clinics with financial incentives. A 2025 investigation by The BMJ revealed that 60% of Phase III trials for fertility drugs like gonadotropins (e.g., Menopur) were sponsored by Merck KGaA and Ferring Pharmaceuticals, which also market estrogen/progesterone regimens for uterine priming. Critics argue this creates a conflict of interest in guidelines that may overstate benefits while downplaying long-term risks.
Conversely, public health advocates like the WHO’s Department of Reproductive Health emphasize that the global burden of advanced maternal age extends beyond fertility. A 2024 WHO report linked pregnancies in women over 50 to a 40% higher risk of neonatal intensive care unit (NICU) admissions due to complications like placental abruption and preterm birth. The organization calls for mandatory pre-conception counseling for women over 45, including discussions on egg freezing ethics and the psychosocial impact of late-life parenting.
—Dr. Rajiv Bahl, Director of Reproductive Health, WHO
“While IVF with donor eggs can be a viable option, we must balance the desire for parenthood with the evidence-based risks to both mother and child. Countries like South Korea have taken a cautious approach, but we need global standards to prevent exploitation of vulnerable women who may face pressure to pursue pregnancy at any cost.”
Contraindications & When to Consult a Doctor
Women considering pregnancy over 50—whether naturally or via IVF—should undergo comprehensive pre-conception screening, including:
- Cardiovascular assessment: Women over 50 have a 3x higher risk of hypertensive disorders (per ACOG), requiring blood pressure monitoring and possible low-dose aspirin prophylaxis.
- Endometrial biopsy: To evaluate uterine receptivity, especially if prior IVF attempts failed. A thin endometrial lining (<8mm) is associated with 70% lower implantation rates.
- Genetic carrier screening: For both parents, as the risk of autosomal recessive disorders rises with age due to accumulated mutations.
Red flags requiring immediate medical evaluation:
- Severe abdominal pain or vaginal bleeding after 12 weeks (possible placental abruption or ectopic pregnancy).
- Sudden swelling in hands/face or proteinuria (>300mg/24h) (signs of pre-eclampsia).
- Fetal growth restriction (<10th percentile on ultrasound) or oligohydramnios (low amniotic fluid), which may require bed rest or delivery.
For women using donor eggs, the American Society for Reproductive Medicine (ASRM) recommends shared decision-making with a fertility specialist to weigh the 5-10% success rate against the 20-30% higher risk of gestational diabetes and preterm delivery.
What Happens Next: The Future of Fertility for Women Over 50
Han Da-geum’s pregnancy will likely accelerate debates over age limits in IVF, particularly in South Korea, where fertility rates have plummeted to 0.78 births per woman—the lowest in the OECD. The Ministry of Health is expected to revisit its 2024 guidelines by late 2026, potentially raising the subsidized age cap to 47, as seen in Spain and Greece. Meanwhile, uterine transplantation—currently experimental—could emerge as an alternative for women with uterine factor infertility, though it carries a 90% failure rate within 5 years, per a 2025 Lancet meta-analysis.
The broader trend is toward personalized fertility medicine, where AI-driven embryo selection (e.g., Genomic Imprinting Analysis) and 3D-printed uterine scaffolds may improve outcomes. However, experts warn that ethical frameworks must evolve to address intergenerational health risks, such as the 2x higher risk of autism in children born to mothers over 50, as documented in a 2026 JAMA Pediatrics study.
The takeaway for expectant mothers—and the public—is clear: while medical advancements offer hope, the risks are not trivial. Han Da-geum’s journey underscores the need for transparent, age-specific counseling, regionally tailored healthcare policies, and longitudinal studies to separate hype from evidence. For now, the data is unequivocal: the older the mother, the higher the stakes.
References
- CDC Assisted Reproductive Technology Report, 2025
- Lancet Study on Advanced Maternal Age, 2023
- ACOG Guidelines on Chromosomal Abnormalities, 2022
- Swedish National Board of Health and Welfare, IVF Coverage Policy
- WHO Universal Health Coverage Index, 2024
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
